Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 4;11(1):29.
doi: 10.3390/metabo11010029.

Gut Microbiota Dysbiosis Is Associated with Elevated Bile Acids in Parkinson's Disease

Affiliations

Gut Microbiota Dysbiosis Is Associated with Elevated Bile Acids in Parkinson's Disease

Peipei Li et al. Metabolites. .

Abstract

The gut microbiome can impact brain health and is altered in Parkinson's disease (PD). The vermiform appendix is a lymphoid tissue in the cecum implicated in the storage and regulation of the gut microbiota. We sought to determine whether the appendix microbiome is altered in PD and to analyze the biological consequences of the microbial alterations. We investigated the changes in the functional microbiota in the appendix of PD patients relative to controls (n = 12 PD, 16 C) by metatranscriptomic analysis. We found microbial dysbiosis affecting lipid metabolism, including an upregulation of bacteria responsible for secondary bile acid synthesis. We then quantitatively measure changes in bile acid abundance in PD relative to the controls in the appendix (n = 15 PD, 12 C) and ileum (n = 20 PD, 20 C). Bile acid analysis in the PD appendix reveals an increase in hydrophobic and secondary bile acids, deoxycholic acid (DCA) and lithocholic acid (LCA). Further proteomic and transcriptomic analysis in the appendix and ileum corroborated these findings, highlighting changes in the PD gut that are consistent with a disruption in bile acid control, including alterations in mediators of cholesterol homeostasis and lipid metabolism. Microbially derived toxic bile acids are heightened in PD, which suggests biliary abnormalities may play a role in PD pathogenesis.

Keywords: Parkinson’s disease; appendix; bile acids; gut; microbiome.

PubMed Disclaimer

Conflict of interest statement

P.B. has received commercial support as a consultant from Axial Biotherapeutics, Calico, CuraSen, Fujifilm-Cellular Dynamics International, IOS Press Partners, LifeSci Capital LLC, Lundbeck A/S, Idorsia and Living Cell Technologies LTD. He has received commercial support for grants/research from Lundbeck A/S and Roche. He has ownership interests in Acousort AB and Axial Biotherapeutics and is on the steering committee of the NILO-PD trial. S.G. receives commercial support as a consultant from Coleman Research and Biogen. No other authors have conflicts of interest.

Figures

Figure 1
Figure 1
The Parkinson’s disease (PD) appendix exhibits shifts in the active microbiota that affect lipid metabolism. Metatranscriptomic analysis was used to determine the changes in the functional microbiota in the PD appendix (n = 12 PD, 16 controls). (a) Microbiota changes in the PD appendix. Metatranscriptome data were analyzed by MetaPhlAn2 and a zero-inflated Gaussian mixture model in metagenomeSeq, adjusting for age, sex, RNA integrity number (RIN), and post-mortem interval. Results are displayed using GraPhlAn, showing the taxonomic tree with the kingdom in the center, and branching outwards to phylum, class, order, family, and genus. Microbial taxa highlighted in red are increased in PD, and blue are decreased in PD (q < 0.05, metagenomeSeq). (b) Microbiota metabolic processes are altered in the PD appendix. Top microbial pathways are altered in PD as identified by HumanN2. Red dashed line denotes q < 0.1 pathways as determined by metagenomeSeq.
Figure 2
Figure 2
Proteomic analysis identifies the altered lipid metabolism pathways in the PD appendix and ileum. Pathway enrichment analysis of proteomic changes in the PD appendix relative to controls (n = 3 PD, 3 controls) (a) and in PD ileum relative to controls (n = 4 PD, 4 controls) (b). Pathway analysis of quantitative proteomic data was performed using g:Profiler. Nodes are pathways altered in the PD appendix that were clustered into functionally similar networks by EnrichmentMap (nodes are q < 0.05 pathways, hypergeometric test). Node size represents the number of genes in the pathway gene set, and the edges connect pathways with similar gene sets (0.7 similarity cutoff). The lipid metabolism pathway network is highlighted in peach. (c) Top 10 proteins that were most consistently altered in the PD appendix and ileum. Heatmap showing the proteins ranked as the most consistently disrupted in the PD appendix and ileum, as determined by a robust ranking algorithm. Log fold change is shown, and red signifies greater disruption in PD.
Figure 3
Figure 3
Increase in the microbiota-derived secondary bile acids in the appendix of PD patients. Bile acid analysis was performed by liquid chromatography–mass spectrometry in the PD and control appendix (n = 15 PD, 12 controls) and ileum (n = 20 PD, 20 controls). Bile acid changes were determined by robust linear regression, controlled for age, sex, and postmortem interval. (a) Illustration of the bile acid changes identified in this study and the bile acid pathway. Primary bile acids are generated in the liver and secondary bile acids are produced by microbiota in the intestine. In the secondary bile acid section of the image, boxes highlight the DCA and LCA groups (DCA, LCA and their respective conjugates). Bile acids increased in the PD appendix or PD ileum, relative to controls, are marked by a blue and green arrow, respectively. The flame symbol denotes hydrophobic bile acids that have proinflammatory effects when elevated. (b) Secondary bile acid changes in the PD appendix and PD ileum. The boxplot center line represents the mean, the lower and upper limits are the first and third quartiles (25th and 75th percentiles), and the whiskers are 1.5× the interquartile range. * p < 0.05, robust linear regression.
Figure 4
Figure 4
Dysfunctional cholesterol and lipid metabolism in the PD ileum. Transcript levels of genes in the ileum (a) and liver (b) affecting the abundance of cholesterol and bile in the enterohepatic circulation. Transcript levels of genes affecting cholesterol and bile acid homeostasis (NR1H2, NR1H3, NR1H4, GPBAR1) and their transport and reabsorption into the enterohepatic circulation (NPC1L1, ABCG5, ABCG8, ASBT, OSTα, OSTβ, FABP6) were examined in the ileum. In the liver, the transcript levels of these genes or the equivalent bile acid transporters (NTCP, FABP1) were examined, as well as the rate-limiting enzymes for bile acid production (CYP7A1, CYP27A1). Transcript levels were analyzed by qPCR and normalized to housekeeping genes (villin1, β-actin). The relative expression ± s.e.m in the ileum (n = 8 PD, 6 controls) and liver (n = 6 PD, 6 controls). * p < 0.05, one-way ANOVA.

References

    1. Ascherio A., Schwarzschild M.A. The epidemiology of Parkinson’s disease: Risk factors and prevention. Lancet Neurol. 2016;15:1257–1272. doi: 10.1016/S1474-4422(16)30230-7. - DOI - PubMed
    1. Kalia L.V., Lang A.E. Parkinson’s disease. Lancet. 2015;386:896–912. doi: 10.1016/S0140-6736(14)61393-3. - DOI - PubMed
    1. Stokholm M.G., Danielsen E.H., Hamilton-Dutoit S.J., Borghammer P. Pathological α-synuclein in gastrointestinal tissues from prodromal Parkinson disease patients. Ann. Neurol. 2016;79:940–949. doi: 10.1002/ana.24648. - DOI - PubMed
    1. Hilton D., Stephens M., Kirk L., Edwards P., Potter R., Zajicek J., Broughton E., Hagan H., Carroll C. Accumulation of α-synuclein in the bowel of patients in the pre-clinical phase of Parkinson’s disease. Acta Neuropathol. 2014;127:235–241. doi: 10.1007/s00401-013-1214-6. - DOI - PubMed
    1. Kim S., Kwon S.-H., Kam T.-I., Panicker N., Karuppagounder S.S., Lee S., Lee J.H., Kim W.R., Kook M., Foss C.A., et al. Transneuronal Propagation of Pathologic α-Synuclein from the Gut to the Brain Models Parkinson’s Disease. Neuron. 2019;103:627–641.e627. doi: 10.1016/j.neuron.2019.05.035. - DOI - PMC - PubMed

LinkOut - more resources